CD20
View article: Supplementary Data Methods from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
Supplementary Data Methods from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia Open
Supplementary methods
View article: Figure S4 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
Figure S4 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia Open
Figure S4 shows 1x104 A20 lymphoma cells were treated with the indicated doses of TAK-981 for 48 hours.
View article: Table S1 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
Table S1 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia Open
Table S1 shows fluorochrome-conjugated anti-human antibodies used for flow cytometry or FACS experiments
View article: Figure S3 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
Figure S3 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia Open
Figure S3 shows Hallmark enrichment plot of RNA collected from naïve T cells from patients with CLL treated with TAK-981
View article: Table S2 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
Table S2 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia Open
Table S2 shows fluorochrome-conjugated anti-mouse antibodies used for flow cytometry experiments
View article: Figure S2 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
Figure S2 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia Open
Figure S2 shows Magnetically enriched CD3+ T cells were activated with 0.5 µg/mL αCD3/28 in the presence of TAK-981 or vehicle control for up to 96 h
View article: Alterations in Resident Immune Cells in Prenatal Trisomy 21 Lungs
Alterations in Resident Immune Cells in Prenatal Trisomy 21 Lungs Open
Respiratory tract infections (RTIs) are amongst the leading causes of hospitalizations in children with Down syndrome (DS). Their elevated susceptibility likely stems from structural differences in the airways and immune system abnormaliti…
View article: Supplementary Data S4 from Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR
Supplementary Data S4 from Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR Open
List of gene names and FPKM values from bulk RNA-seq on unstimulated ex vivo-cultured T cells (Fig. 4F).
View article: Supplementary Data S1 from Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR
Supplementary Data S1 from Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR Open
A curated list of 2493 T-cell–relevant gene sets selected from current Molecular Signatures Database (MSigDB) gene sets.
View article: Figure 1 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade
Figure 1 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade Open
High-level cell type atlas of the PDAC tumor microenvironment. A, UMAP embedding of scRNA-seq data from 3 PDAC patient samples overlaid with high level cell type annotation (i). UMAP embedding overlaid with sample identification, an…
View article: Cure of a CD20-positive peripheral T-cell lymphoma-NOS with CHOPE regimen plus surgery a case report and literature review
Cure of a CD20-positive peripheral T-cell lymphoma-NOS with CHOPE regimen plus surgery a case report and literature review Open
Peripheral T-cell lymphoma non-specific type (PTCL-NOS) is the most common subtype of mature T-cell tumors, which is clinically characterized by high invasiveness and poor prognosis. It is worth noting that PTCL-NOS rarely abnormally expre…
View article: Supplementary Figures S1 to S7 from Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR
Supplementary Figures S1 to S7 from Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR Open
Figures S1 to S7
View article: Fluid overload-associated large B-cell lymphoma: two case report and review of literature
Fluid overload-associated large B-cell lymphoma: two case report and review of literature Open
Background Fluid overload-associated large B-cell lymphoma (FO-LBCL) is an exceptionally rare lymphoma characterized by predominant involvement of serous body cavities—such as the pleura, peritoneum, and pericardium—in the absence of a sol…
View article: Supplementary Data S2 from Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR
Supplementary Data S2 from Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR Open
List of gene names and FPKM values from bulk RNA-seq on T cells harvested from tumor-bearing mice (Fig. 4A-D, F and Supplementary Fig. S7).
View article: B Cell Differentiation Model for Identifying Predictors of Responses to Rituximab‐Mediated B Cell Depletion in Rheumatic Diseases
B Cell Differentiation Model for Identifying Predictors of Responses to Rituximab‐Mediated B Cell Depletion in Rheumatic Diseases Open
Rituximab (RTX), an anti‐CD20 monoclonal antibody, has been used to treat autoimmune diseases such as rheumatoid arthritis (RA). However, variability in therapeutic response to RTX remains a challenge. Here, a systems model is developed to…
View article: Figure 3 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
Figure 3 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia Open
Effect of NKCEs targeting CD19 or CD20 on primary BCP-ALL cells. A, Phenotypic characterization via flow cytometry of four BCP-ALL primary leukemia samples, using CD45-APC-Vio770, CD19-PE-Cy7, and CD20-V450. B, 7AAD/AnnV stai…
View article: Figure 1 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
Figure 1 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia Open
Effect of NKCEs targeting CD19 or CD20 on BCP-ALL cell lines. A, Two pediatric BCP-ALL cell lines were characterized for the surface expression of CD19 and CD20 via flow cytometry using specific mAbs followed by PE-conjugated anti-I…
View article: Supplementary Figure S1 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy
Supplementary Figure S1 from CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy Open
Supplementary Figure S1. Tumor volume in CD49d+ and CD49d− CLL during acalabrutinib treatment
View article: MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma
MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma Open
This phase 2 study evaluated the efficacy and safety of combining acalabrutinib (A) and lenalidomide (L) with either rituximab (ALR) or obinutuzumab (ALO), with longitudinal minimal residual disease (MRD) monitoring in frontline MCL treatm…
View article: Figure 4 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
Figure 4 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia Open
CD19-NKCEs efficiently promote NK-cell antileukemia activity in a transplantation setting. A, Evaluation of NKp46, NKp30, CD16, perforin, and granzyme B expression in NK cells from transplanted patients (Post1–3M; n = 12) and…
View article: Clinical and pathological analysis of intravascular large B-cell lymphoma of the prostate
Clinical and pathological analysis of intravascular large B-cell lymphoma of the prostate Open
Background Intravascular large B-cell lymphoma is a rare type of lymphoma. Although this tumor can occur in several parts of the body, primary intravascular large B-cell lymphoma of the prostate is extremely rare. Currently, there are only…
View article: Supplementary Table S4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Supplementary Table S4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses Open
Supplemental Table S4 - Flow cytometry antibody list
View article: Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses Open
Supplemental Table S2 - Differential expression analysis of genes in leukemic or immune cells treated with sEV
View article: CXCR3 expression on antigen-experienced B cells is systemically dysregulated in type 1 diabetes
CXCR3 expression on antigen-experienced B cells is systemically dysregulated in type 1 diabetes Open
Aims/hypothesis The chemokine receptor C-X-C chemokine receptor type 3 (CXCR3) is a key chemoattractant molecule that facilitates the migration of activated T cells to the pancreas, leading to beta cell death. In this study, we investigate…
View article: Case Report: Angioimmunoblastic T-cell lymphoma with coexisting plasma cell tumors: three cases and review of the literature
Case Report: Angioimmunoblastic T-cell lymphoma with coexisting plasma cell tumors: three cases and review of the literature Open
Angioimmunoblastic T cell lymphoma (AITL) is classified as a nodal T-cell lymphoma from T follicular helper(Tfh) cells. Dysfunctional Tfh cells can lead to abnormal B cell regulation and plasma cell differentiation in AITL. However, the co…
View article: Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial
Reply to: Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial Open
View article: Advances and prospects of CAR-T cell therapy in autoimmune disease treatment
Advances and prospects of CAR-T cell therapy in autoimmune disease treatment Open
Autoimmune diseases, owing to their chronic onset and immune imbalance, seriously affect the quality of life of patients. Existing treatment methods have limited efficacy and significant side effects. Chimeric antigen receptor (CAR)-based …
View article: Obinutuzumab in kidney transplantation: Past, present, and future
Obinutuzumab in kidney transplantation: Past, present, and future Open
Antibody-mediated rejection (ABMR) and recurrent primary renal disease (PRD) represent major causes of kidney transplant (KT) loss. The standard of care for desensitization, ABMR, and relapsing autoimmune glomerulopathies or nephrotic synd…
View article: CD20+ and CD204+ exhibit distinct prognostic associations in thymic epithelial tumors
CD20+ and CD204+ exhibit distinct prognostic associations in thymic epithelial tumors Open
Introduction Thymic epithelial tumors (TETs), encompassing thymomas and thymic carcinomas, are rare malignancies originating from thymic epithelial cells. This study aimed to characterize tumor-infiltrating immune cells (TIIC) within the t…
View article: Tonsillar Hypertrophy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Mini-Review
Tonsillar Hypertrophy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Mini-Review Open